Sutter Health Hospitals Deploy Wearable Ultrasound Tech to Personalize Fluid Management for Sepsis
IV fluid overload is a common complication in emergency and intensive care settings, in part because predicting a patient's response to fluids is complex. Individual needs can vary widely and shift quickly during critical illness. In studies of patients with sepsis and septic shock – a life-threatening condition caused by the body's overwhelming response to infection – nearly one-third were found to be fluid unresponsive¹. Without early identification of fluid unresponsiveness, patients may receive excessive fluids, increasing their risk of serious complications such as pulmonary edema, where fluid accumulates in the lungs. By some estimates, fluid overload can extend the average hospital stay by three days and increase healthcare costs by more than $15,000 per patient².
FloPatch is an FDA-cleared, wearable device that provides clinicians with a fast and non-invasive way to perform hemodynamic assessments, measuring a patient's heart and blood flow response to IV fluids to help guide personalized fluid therapy. Clinical studies have shown that dynamic fluid assessments can reduce the need for mechanical ventilation and renal replacement therapy³,⁴, decrease ICU length of stay⁴, and are associated with lower mortality⁵.
'Our previous method of assessing fluid responsiveness was cumbersome and time-consuming. We often had to pull ICU nurses to perform evaluations in other units, which was disruptive and inefficient,' said Dr. Nader Emami, ICU medical director at Sutter Santa Rosa Regional Hospital. 'FloPatch streamlines the process with a simple, wearable device that empowers any member of the care team to perform this essential assessment faster and easier.'
'In emergency care, we often treat patients with complex needs, including people with sepsis,' said Dr. John Skovran, Emergency Department medical director at Sutter's Alta Bates Summit Medical Center, Summit Campus. 'We need a fast, reliable way to determine whether they'll benefit from fluids or be harmed by them. FloPatch gives us that clarity at the bedside in minutes, helping us make confident, timely decisions.'
Joe Eibl, chief executive officer and co-founder of Flosonics Medical, noted: 'Sutter Health's multisite adoption of FloPatch reflects a growing recognition that wearable, real-time technologies play a transformative role in patient care. It's a great example of how forward-thinking health systems are meeting critical challenges with innovation.'
Sutter Health prioritized staff training and thoughtfully integrated FloPatch into clinical workflows to make it a seamless part of care in intensive care and emergency medicine departments.
About Sutter Health:
Sutter Health is a not-for-profit healthcare system dedicated to providing comprehensive care throughout California. Committed to health equity, community partnerships, and innovative, high-quality patient care, Sutter Health is pursuing a bold new plan to reach more people and make excellent healthcare more connected and accessible. Currently serving more than 3.5 million patients, thanks to our dedicated team of more than 60,500 employees and clinicians, and 14,000+ physicians and advanced practice clinicians, with a unified focus on expanding care to serve more patients.
Sutter delivers exceptional and affordable care through its hospitals, medical groups, ambulatory surgery centers, urgent care clinics, telehealth, home health, and hospice services. Dedicated to transforming healthcare, at Sutter Health, getting better never stops.
Learn more about how Sutter Health is transforming healthcare at sutterhealth.org and vitals.sutterhealth.org.
About Flosonics Medical:
Flosonics Medical is a medical device company engaged in the research and development of innovative ultrasound technology. Founded in 2015, the company's mission is to improve patient care and the practice of medicine through technology-enabled solutions and groundbreaking clinical research. For more information, please visit www.flosonicsmedical.com.
References:
¹ Hernández G, Ospina‑Tascón GA, Damiani LP, et al; ANDROMEDA‑SHOCK Investigators. Effect of a resuscitation strategy targeting peripheral perfusion status vs serum lactate levels on 28‑day mortality among patients with septic shock: the ANDROMEDA‑SHOCK randomized clinical trial. JAMA. 2019 Feb 19;321(7):654–664. doi:10.1001/jama.2019.0071
² American Hospital Directory analysis of FFY2022 Medicare IPPS (MedPAR) claims data
³ Douglas IS, Alapat PM, Corl KA, Exline MC, Forni LG, Holder AL, et al. Fluid Response Evaluation in Sepsis Hypotension and Shock: A Randomized Clinical Trial. Chest. 2020 Oct;158(4):1431–1445. doi:10.1016/j.chest.2020.04.025
⁴ Latham HE, Bengtson CD, Satterwhite L, et al. Stroke volume–guided resuscitation in severe sepsis and septic shock improves outcomes. J Crit Care. 2017 Dec;42:42–46. doi:10.1016/j.jcrc.2017.06.028
⁵ Dubin A, Loudet C, Kanoore Edul VS, et al. Characteristics of resuscitation, and association between use of dynamic tests of fluid responsiveness and outcomes in septic patients: results of a multicenter prospective cohort study in Argentina. Ann Intensive Care. 2020 Apr 15;10(1):40. doi:10.1186/s13613-020-00659-7
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Ex-FDA chief wants to regulate big food
Former FDA chief Dr. David Kessler is petitioning the agency to strip refined carbs of their 'safe' status, arguing they fuel major diseases. The move comes as the CDC says ultra-processed foods make up over half the U.S. diet, including most kids' meals. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed. Solve the daily Crossword
Yahoo
an hour ago
- Yahoo
Popular sweetener recalled over labeling mix-up as FDA issues warning
Double check your sweetener before adding it to your coffee or tea. NuNaturals, a company known for its zero-sugar sweeteners, baking items, and other goods, issued a voluntary recall of certain Organic Monk Fruit and Stevia sweeteners in July. A labeling mix-up revealed that bottles labeled as Stevia were filled with the monk fruit sweetener and vice versa. Now, the recall has been elevated by the FDA to a Class II, the second-highest risk level. A Class II recall is 'a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote,' according to the FDA. The mislabeling can pose a serious health risk to those allergic to ragweed and related plants, as they may have a sensitivity to stevia. Monk fruit allergies, though rare according to WebMD, are also possible. The severity of an allergic reaction can vary from mild irritation to potential complications including anaphylaxis, resulting in respiratory problems. NuNaturals said 78 bottles of the Monk Fruit and 78 bottles of the Stevia sweeteners were affected by the recall. Affected Pure Monk Fruit Sweetener bottles have the UPC code: 7 39223 00187 and lot number: 25104S. Organic Pure Stevia bottles have the UPC code: 7 39223 00204 0 and lot number: 25104S. Specific information on where the mislabeled bottles were sold was not made available. The NuNautrals recall is the latest in a string of mislabelling recalls affecting consumers. In late July, High Noon Hard Seltzers were recalled over a labeling error. Some cans, filled with High Noon Vodka Seltzer, were mislabeled as the non-alcoholic Celsius Astro Vibe Energy Drink, Sparkling Blue Razz Edition. As a result, drinking the beverage in these cans can result in unintentional alcohol consumption. However, no illnesses or adverse events have been reported to date. Prior to that, a voluntary recall was initiated July 14 by food ingredient company Bunge North America, affecting 1,800 cases of its NH European Style Butter Blend, which did not declare milk as an allergen on the label. Over 64,000 pounds of the contaminated butter was sent to 12 distribution centers located throughout the U.S., as well as a single distribution center located in the Dominican Republic. Affected cases were packaged in white paperboard and contained 36 blocks.
Business Upturn
5 hours ago
- Business Upturn
Folqs Highlights First-Day, Grass-Fed Colostrum Powder Amid Global Surge in Demand
Wilmington, DE, Aug. 08, 2025 (GLOBE NEWSWIRE) — Folqs, a U.S.-based wellness company, introduces new consumer product, Folqs First-Day Colostrum Powder . This positions the company within the growing colostrum supplement sector, which has recently exceeded $3 billion in global market value, according to industry research. The product is formulated from bovine colostrum collected on the first day after birth and sourced exclusively from grass-fed, pasture-raised cows located in the United States. Processing and packaging are conducted domestically at an FDA-registered facility that operates under Current Good Manufacturing Practices (cGMP). This announcement marks Folqs' formal entry into a sector experiencing measurable growth. A 2025 report from Grand View Research estimates the global colostrum market will sustain a compound annual growth rate of approximately 7% through 2030. Concurrently, online search interest in colostrum-related supplements has risen 68% year-over-year, based on recent data from Google Trends. Product Developed for Adults Focused on Dietary Supplementation According to the company, Folqs First-Day Colostrum Powder is unflavoured and designed to dissolve quickly into liquids. It is intended for use by adults who are exploring food-based supplement options. The product contains naturally occurring bioactive compounds found in colostrum, including immunoglobulins and growth factors Folqs has indicated it does not add any artificial ingredients or flavoring agents during production. The colostrum used is collected only after the needs of the newborn calf have been met, under a sourcing policy the company refers to as 'Calf-First.' This policy stipulates that calves receive their full share before any surplus is gathered for human use. Each batch undergoes third-party testing, with screening for microbiological content, heavy metals, and nutritional composition. Documentation of testing is maintained for internal quality control and regulatory compliance. Market Timing Reflects Broader Consumer Shift Toward Food-Based Supplements The decision to launch into the colostrum segment comes at a time when consumer attention to supplement sourcing and transparency has intensified. Data from the Council for Responsible Nutrition (2024) indicates that only 52% of U.S. supplement users consider product labels to be 'very trustworthy.' Folqs' leadership said that these statistics informed its approach to formulation, production, and consumer messaging. 'Consumers are tired of vague 'proprietary blends.' By sharing our lab reports and guaranteeing results, we're setting a new transparency bar for the $3 billion colostrum space,' said David Johnson, Company Spokesperson. Johnson noted that Folqs will prioritize third-party testing as part of its operational model. 'We've aligned our product development process with the demand for greater transparency in supplement sourcing,' Johnson said. 'Every decision, from raw ingredient origin to packaging, was shaped by current expectations in the space.' Availability and Purchasing Details Folqs First-Day Colostrum Powder is exclusively available through the company's official website, Pricing, serving guidelines, and detailed product specifications are provided on the site. No retail or third-party distribution agreements were announced at the time of release. The product is offered under a customer refund policy referred to as the 90-Day Money-Back guarantee, allowing purchasers to request a refund if unsatisfied. Folqs stated that this policy was introduced to address consumer hesitations common in the dietary supplement category. No Comparisons or Claims Made Against Competing Brands Under established content distribution standards, Folqs has not made any comparative statements regarding other colostrum products on the market. Folqs emphasized that its entry into the colostrum market is grounded in sourcing and production controls, rather than marketing-driven distinctions. It has not used or referenced any competing companies or their product names in its communications. Regulatory and Testing Framework The colostrum is processed in a facility that meets federal registration and cGMP compliance criteria. Third-party laboratories are used to conduct batch testing. All production occurs within the United States, and the company maintains that its supply chain remains fully domestic at this time. No claims have been made about the product's ability to prevent, treat, or cure any medical condition. The company has not submitted its product for review by the Food and Drug Administration, as it is sold as a dietary supplement and not a drug. About Folqs Folqs is a privately held wellness company headquartered in Wilmington, Delaware. It specializes in sourcing and manufacturing food-based supplements. The company's operational focus includes domestic production, third-party testing, and ingredient transparency. Folqs First-Day Colostrum Powder is its first product offering. Media Contact Company Name: FolqsContact Person: David Johnson Email: [email protected] Phone: 800-975-4495Country: United States Website:
